ADC Therapeutics SA

ADC Therapeutics SA (ADCT) priced its initial public offering on May 18, 2020 at $19.00 per share, above its $16.00–$18.00 range, and listed on NYSE. At the IPO price its market capitalization was about $1.31B. Davis Polk advised the company and Cooley advised the underwriters.

ADC Therapeutics SA is a late clinical-stage, oncology-focused biotechnology company developing antibody drug conjugates using pyrrolobenzodiazepine technology for hematological malignancies and solid tumors. Its hematology candidates include loncastuximab tesirine and camidanlumab tesirine, and it is preparing for a first product launch if approved.

Status

IPO

Ticker

ADCT

Exchange

NYSE

Priced

May 18, 2020

IPO price

$19.00

Price range

$16.00–$18.00

Market cap at IPO price

$1.31B

First filed

Sep 6, 2019

Company counsel

Davis Polk

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

Switzerland

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.